Brenda Khan
Fen-phen was a weight-loss medication that combined fenfluramine and phentermine. It was introduced in the early 1990s and was initially believed to be a safe and effective treatment for obesity. However, in 1997, it was abruptly pulled from the market due to reports of severe cardiac side effects, including valvular heart disease and pulmonary hypertension. Following the withdrawal of fen-phen, new medications such as semaglutide have emerged, aiming to provide safe and effective weight loss solutions with a low incidence of severe side effects.
| Characteristics | Values |
|---|---|
| Name | Fen-phen |
| Combination of drugs | Fenfluramine and phentermine |
| Alternative combination | Dexfenfluramine and phentermine (Dexfen-Phen) |
| Fenfluramine brand names | Pondimin, Redux |
| Phentermine brand name | Adipex-P |
| Side effects | Fast heart rate, high blood pressure, trouble sleeping, dizziness, restlessness, valvular heart disease, pulmonary hypertension, cardiac-valve regurgitation |
| Withdrawal from market | September 1997 |
| Lawsuits | Over 50,000 product liability lawsuits, total liability estimated to be as high as $14 billion |
Explore related products
What You'll Learn
Fen-phen's popularity and decline
Fen-phen, a combination of fenfluramine and phentermine, was a popular anti-obesity medication in the early 1990s. The individual drugs were approved for short-term use in the 1970s but were not very effective. However, in 1979, Dr. Michael Weintraub had the idea to combine the two drugs, which had different actions on the brain. This combination was found to be more effective in treating obesity without causing the side effects of previous diet drugs.
Fen-phen gained immense popularity as a wonder drug that could help people lose weight faster than diet and exercise. It was heavily marketed in the 1990s and gained notoriety as an easy way to lose weight. An estimated six million Americans, most of them women, took fen-phen, and it was even tested on children. However, the popularity of fen-phen was based on a single study involving just 121 patients.
In 1996, a 30-year-old woman developed heart problems after taking fen-phen for a month and died in February 1997. This prompted a paper in the New England Journal of Medicine in August 1997, which discussed clinical findings suggesting a possible correlation between mitral valve dysfunction and the use of fen-phen. The FDA received additional reports of valvular heart disease and pulmonary hypertension in people taking fen-phen, and in September 1997, they requested its withdrawal from the market. Follow-up studies showed that for people who took the combination for 3 months or less, the rate of heart valve complications was less than 3%.
After fen-phen was withdrawn from the market, its manufacturer, American Home Products, faced thousands of lawsuits from injured parties. In April 2005, American Lawyer magazine reported that more than 50,000 product liability lawsuits had been filed, with total liability estimated to be as high as $14 billion.
Baby Acne: Is Mom's Diet to Blame?
You may want to see also
Explore related products
Fen-phen side effects
Fen-phen, a combination of fenfluramine and phentermine, was a popular weight loss therapy in the 1990s. However, it was discovered that fen-phen had serious side effects, including:
- Valvular Heart Disease (VHD): This involves the deterioration of one or more valves of the heart, specifically the aortic and mitral valves on the left and the pulmonary and tricuspid valves on the right.
- Primary Pulmonary Hypertension (PPH): This is a condition where the pulmonary arteries, which carry deoxygenated blood from the right side of the heart to the lungs, become narrowed and scarred. PPH can lead to an increased heart rate, shortness of breath, and light-headedness during activity, and can ultimately result in heart failure and death.
- Other side effects of phentermine: These include a fast heart rate, high blood pressure, trouble sleeping, dizziness, and restlessness. Phentermine may also be habit-forming.
In 1997, the FDA requested the withdrawal of fen-phen from the market due to these serious side effects. Despite this, thousands of people have been affected by the drug, and lawsuits against the manufacturer, Wyeth, are still ongoing.
Psyllium Husk for Toddlers: An Easy Guide for Parents
You may want to see also
Explore related products
Fen-phen lawsuits
Fen-phen was a weight-loss protocol heavily marketed in the 1990s that included fenfluramine (sold as Pondimin) or dexfenfluramine (sold as Redux). Fen-phen was shown to cause damage to the mitral and aortic heart valves, as well as a serious lung condition called primary pulmonary hypertension. This led to its withdrawal from the market in 1997 and sparked a wave of lawsuits and claims that are still being filed and paid.
In 1996, a 30-year-old woman developed heart problems after a month of using fen-phen; when she died in February 1997, the Boston Herald devoted a front-page article to her. In August 1997, a paper in the New England Journal of Medicine (NEJM) from the Mayo Clinic discussed clinical findings in 24 people who had taken fen-phen, suggesting a possible correlation between mitral valve dysfunction and the use of these anorectic agents. The FDA subsequently received over a hundred additional reports of valvular heart disease in people taking fen-phen, fenfluramine alone, or dexfenfluramine alone.
In 1997, the FDA requested the withdrawal of fen-phen from the market, responding to findings from doctors who had evaluated people taking these two drugs with echocardiograms. The findings indicated that approximately 30% of people who had taken the combination for up to 24 months had abnormal echocardiograms, even though they had no symptoms. This led to fen-phen's fall from grace as a "diet miracle".
Following the withdrawal of fen-phen, thousands of lawsuits were filed against American Home Products (later known as Wyeth) for cardiovascular injuries. In August 2000, a settlement with American Home Products was approved for $4.75 billion to cover both medical monitoring and compensation for patients who suffered damages. The class of plaintiffs grew to nearly 600,000, and the fen-phen settlement is now valued at $7.65 billion.
In 2005, American Lawyer magazine reported that more than 50,000 product liability lawsuits had been filed by alleged fen-phen victims, with total liability estimated to be as high as $14 billion. Wyeth offered settlements ranging from $5,000 to $200,000, but thousands of injured persons rejected these offers. As of 2025, fen-phen lawsuits and claims are still being filed and paid, with law firms such as CK Law Firm and Lieff Cabraser representing injured individuals.
Liquid Diets: What to Eat and What to Avoid
You may want to see also
Explore related products
Fen-phen alternatives
Fen-phen, a combination of fenfluramine and phentermine, was a popular anti-obesity medication in the 1990s. However, due to reports of serious side effects, including valvular heart disease and pulmonary hypertension, it was withdrawn from the market in 1997. As a result, those seeking weight loss treatments may be interested in Fen-phen alternatives. Here are some options to consider:
Wegovy (Semaglutide): This is a once-weekly prescription injectable medication that was approved by the FDA in June 2021. It is indicated for adults with a BMI of 30 or higher or a BMI of 27 or higher with weight-related conditions.
Saxenda (Liraglutide): This is another injectable medication that has been approved by the FDA since 2014. It is approved for use in adults with a BMI of 30 or higher or 27 or higher with weight-related conditions such as high blood pressure, type 2 diabetes, and high cholesterol.
Other Prescription Weight Loss Drugs: There are other FDA-approved weight loss medications available, such as phentermine itself, which is still prescribed today. However, it is important to note that phentermine has its own side effects and may not be suitable for everyone, especially those with a history of substance abuse disorder.
Lifestyle Changes: While not a direct alternative to Fen-phen, making lifestyle changes such as adopting a healthier diet, increasing physical activity, and modifying behaviours can be effective tools in weight management. This was part of Dr. Michael Weintraub's original vision for treating obesity as a chronic disease.
It is important to consult with a healthcare professional before starting any weight loss treatment to ensure it is safe and appropriate for your individual needs.
Dieting and Insulin Resistance: A Complex Relationship
You may want to see also
Explore related products
Fen-phen cardiac risks
Fen-phen, a combination of fenfluramine and phentermine, was a popular weight-loss drug in the 1990s. However, it was pulled from the market in 1997 due to serious cardiac risks that came to light.
The cardiac risks associated with fen-phen include potentially fatal pulmonary hypertension and heart valve problems. In 1994, concerns were raised about fenfluramine's labelling, which reported only four cases of pulmonary hypertension when 41 had been observed. Despite this, no action was taken until 1996.
In 1996, a 30-year-old woman developed heart problems after taking fen-phen for a month. Unfortunately, she passed away in February 1997, and her story made the front page of the Boston Herald. This tragedy brought further attention to the potential cardiac risks of fen-phen.
In August 1997, a paper in the New England Journal of Medicine reported clinical findings in 24 people who had taken fen-phen. The authors suggested a possible correlation between mitral valve dysfunction and the use of these anorectic agents. The FDA received additional reports of valvular heart disease in people taking fen-phen or its components, leading to a request for manufacturers to stress the potential cardiac risks on drug labels and in package inserts.
Follow-up studies revealed that the rate of heart valve complications was less than 3% for those who took the combination for three months or less. However, for those who took it for up to 24 months, approximately 30% had abnormal echocardiograms, indicating heart valve issues even without symptoms. This disparity in complication rates based on duration of use underscores the serious nature of fen-phen's cardiac risks.
Diet Pills: Intestinal Impact and Side Effects
You may want to see also
Frequently asked questions
Fen-Phen is the popular name given to the combination of appetite suppressants fenfluramine and phentermine. It was sold in the early 1990s and used to treat patients with severe obesity problems.
Fen-Phen was discontinued in 1997 after reports of severe cardiac issues, including valvular heart disease and pulmonary hypertension, in people who took the drug.
Following the discontinuation of Fen-Phen, the FDA issued a public health advisory and requested that healthcare providers send in patient information on any adverse effects from taking the combination of drugs. Over 50,000 product liability lawsuits were filed by alleged victims, with total liability estimated to be as high as $14 billion.
Yes, new medications such as semaglutide have proven to be safe and effective weight-loss treatments, with a low incidence of severe side effects.
